MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Femasys Inc.

< Previous 1 2 3 Next >
News headline image
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces Third Quarter Financial Results for 2025
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Announces Second Quarter Financial Results for 2025
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
News headline image
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story